甲狀旁腺激素(PTH)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Parathyroid Hormone (PTH) ,etc. by FLIA (Flow Luminescence Immunoassay)
iPTH; Intact Parathyroid Hormone; Parathormone; Parathyrin
（注：?jiǎn)未位鞙y(cè)多因子不超過(guò)8個(gè)指標(biāo) ）
- 編號(hào)ULMA866Po
- 物種Sus scrofa; Porcine (Pig，豬) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法競(jìng)爭(zhēng)抑制
- 反應(yīng)時(shí)長(zhǎng)1.5h
- 檢測(cè)范圍0.98-1000pg/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.327 pg/mL.
- 樣本類型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格 ¥ 1415 ¥ 1469 ¥ 1551 ¥ 1660 ¥ 1769 ¥ 1932 ¥ 2177 ¥ 2721 添加到價(jià)格計(jì)算器 計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)甲狀旁腺激素(PTH)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的甲狀旁腺激素(PTH)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 99-105 | 102 |
| EDTA plasma(n=5) | 95-105 | 99 |
| heparin plasma(n=5) | 83-97 | 93 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的甲狀旁腺激素(PTH)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中甲狀旁腺激素(PTH)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 87-96% | 90-101% | 83-103% | 78-93% |
| EDTA plasma(n=5) | 80-95% | 83-94% | 87-96% | 84-95% |
| heparin plasma(n=5) | 92-101% | 85-94% | 78-105% | 97-104% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品、樣本、磁珠、檢測(cè)溶液A）標(biāo)準(zhǔn)品或樣本50μL及磁珠10μL，加檢測(cè)溶液A50μL，
37°C酶標(biāo)板振蕩器孵育60分鐘；
3. 磁吸洗板3次；
4. 加檢測(cè)溶液B100μL，37°C振動(dòng)孵育30分鐘；
5. 磁吸洗板3次；
6. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將甲狀旁腺激素(PTH)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠、標(biāo)記VEGFA，標(biāo)記的甲狀旁腺激素(PTH)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)和未標(biāo)記的甲狀旁腺激素(PTH)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體競(jìng)爭(zhēng)結(jié)合，然后將未結(jié)合物洗凈后，加入PE標(biāo)記的親和素，再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的甲狀旁腺激素(PTH)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)呈負(fù)相關(guān)。
贈(zèng)品
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Sus scrofa; Porcine (Pig，豬) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA866Po01 | 甲狀旁腺激素(PTH)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA866Po01 | 甲狀旁腺激素(PTH)多克隆抗體 | WB |
| ULAA866Po81 | 甲狀旁腺激素(PTH)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| ULAA866Po71 | 甲狀旁腺激素(PTH)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| UMAA866Po21 | 甲狀旁腺激素(PTH)單克隆抗體 | WB; IHC; ICC; IP. |
| UCEA866Po | 甲狀旁腺激素(PTH)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMA866Po | 甲狀旁腺激素(PTH)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Biological trace element research | Elevation of PTH and PTHrp Induced by Excessive Fluoride in Rats on a Calcium-deficient Diet [PubMed: 19915804] |
| Basic nutritional investigation | Effects of duodenal redox status on calcium absorption and related genes expression in high-fat diet–fed mice [ScienceDirect: S0899900709004808] |
| The Korean Journal of Nutrition | Effects of a Low Calcium Diet and Oxalate Intake on Calcium Deposits in Soft Tissues and Bone Metabolism in Ovariectomized Rats [KoreaMed: source] |
| Acta Physiologica Hungarica | Whole body vibration is a safe exercise training method and induces no impaired alterations on rat plasma parameters [Pubmed: 22173025] |
| Toxicology and Industrial Health | The effect of supplementation of calcium, vitamin D, boron, and increased fluoride intake on bone mechanical properties and metabolic hormones in rat [PubMed: 22782709] |
| Indian Journal of Experimental Biology | Effect of consumption of fatty acids, calcium, vitamin D and boron with regular physical activity on bone mechanical properties and corresponding metabolic hormones in rats. [PubMed: 22439438] |
| Plos one | Is Gastrectomy-Induced High Turnover of Bone with Hyperosteoidosis and Increase of Mineralization a Typical Osteomalacia? [PubMed: PMC3679169] |
| Nutr Hosp. | Effect of the “protein diet” and bone tissue. [Pubmed: 24483972] |
| Clinical Cancer Research | Zoledronic acid has differential anti-tumour activity in the pre-and post-menopausal bone microenvironment in vivo [Aacrjournals: Source] |
| Nutricion Hospitalaria | Effect of the “protein diet” and bone tissue [Aulamedica: Source] |
| Academic Journal | Effect of whole body vibration on healthy rat plasma parameters [Ebscohost: Source] |
| J Proteome Res. | Biomarkers identified by urinary metabonomics for noninvasive diagnosis of nutritional rickets [Pubmed:25051233] |
| Medicine (Baltimore) | An Attempt to Evaluate Selected Aspects of “Bone–Fat Axis” Function in Healthy Individuals and Patients With Pancreatic Cancer [PubMed: 26266370] |
| J Nutr Sci Vitaminol (Tokyo) | The Impact of Different Amounts of Calcium Intake on Bone Mass and Arterial Calcification in Ovariectomized Rats [PubMed: 26639847] |
| The Korean Society of Pharmacognosy | Effects of Oryza sativa L. Aleurone Layer Extract on Bone Mineral Density and Bone-related Markers in the Ovariectomized Rat [Article: Hksobf_2015_V46N2_167] |
| J?Bone?Miner Res | Fat and Sucrose Intake Induces Obesity‐Related Bone Metabolism Disturbances: Kinetic and Reversibility Studies in Growing and Adult Rats [Pubmed:26175082] |
| 7 | Cell-matrix signals specify bone endothelial cells during developmental osteogenesis. [pubmed:28218908] |
| PLOS?ONE | Prostaglandin-E2?Mediated?Increase?in?Calcium?and?Phosphate?Excretion?in a?Mouse?Model?ofDistal?Nephron?Salt?Wasting. [pubmed:27442254] |
| International Journal of Advanced Research in Biological Sciences | Effects of fatty acids, nutrients and whole body vibration on bone histomorphometry, mechanical properties and metabolic parameters in male rat [10.22192/ijarbs.2017.04.04.018] |
| American Journal of Physiology-Renal?Physiology | Chronic nicotine exposure reduces klotho expression and triggers different renal and hemodynamic responses in -haploinsufficient mice [Pubmed:29363324] |
| Tropical?Animal?Health?and Production | Dietary supplementation for Santa Inês hair ewes on pasture at pre-and postpartum periods: dry matter intake, digestibility, milk production, and mineral metabolism [Pubmed:29931604] |
| International Immunopharmacology | CD8+ T lymphocytes enhance the anabolic effect of intermittent parathyroid hormone on cementoblasts [Pubmed: 31679847] |
| ENDOCRINOLOGY | A New Therapeutic Approach Using a Calcilytic (AXT914) for Post-Surgical Hypoparathyroidism in Female Rats [Pubmed: 32852547] |
| Kidney International | Calciprotein particles regulate fibroblast growth factor-23 expression in osteoblasts. [] |
| PREVENTIVE AND/OR THERAPEUTIC AGENT FOR OSTEOGENESIS IMPERFECTA AND OTHER DISEASES [] | |
| Oxid Med Cell Longev | Long-Term Administration of Abacavir and Etravirine Impairs Semen Quality and Alters Redox System and Bone Metabolism in Growing Male Wistar Rats [34373766] |
| Gene Therapy | Correction of a knock-in mouse model of acrodysostosis with gene therapy using a rAAV9-CAG-human PRKAR1A vector [34599290] |
| Cells | Calreticulin Shortage Results in Disturbance of Calcium Storage, Mitochondrial Disease, and Kidney Injury [Pubmed:35456008] |
| African Health Sciences | Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease [] |
